Lenacapavir

Lenacapavir is an HIV capsid inhibitor developed by Gilead Sciences. Currently, it is being evaluated in phase II/III trials for people with multidrug-resistant HIV. Laboratory studies indicate the drug is unaffected by mutations associated with resistance to most approved antiretroviral therapies. Watch the animation to see how researchers think that Lenacapavir blocks HIV entry into the nucleus. 

  • Bester SM, Wei G, Zhao H, et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. Oct 16 2020;370(6514):360-364. doi:10.1126/science.abb4808

    Burdick RC, Li C, Munshi M, et al. HIV-1 uncoats in the nucleus near sites of integration. Proc Natl Acad Sci U S A. Mar 10 2020;117(10):5486-5493. doi:10.1073/pnas.1920631117

    Jang S, Cook NJ, Pye VE, et al. Differential role for phosphorylation in alternative polyadenylation function versus nuclear import of SR-like protein CPSF6. Nucleic Acids Res. May 21 2019;47(9):4663-4683. doi:10.1093/nar/gkz206

    Matreyek KA, Yücel SS, Li X, Engelman A. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog. 2013;9(10):e1003693. doi:10.1371/journal.ppat.1003693

    Yant SR, Mulato A, Hansen D, et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat Med. Sep 2019;25(9):1377-1384. doi:10.1038/s41591-019-0560-x

    Zila V, Margiotta E, Turoňová B, et al. Cone-shaped HIV-1 capsids are transported through intact nuclear pores. Cell. Feb 18 2021;184(4):1032-1046.e18. doi:10.1016/j.cell.2021.01.025